Role of hepatitis C virus genotype 3 in liver fibrosis progression : a systematic review and meta-analysis ; et, Impact of nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic by Probst, A.
UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE 
Département de médecine 
Service des maladies infectieuses 
« Role of Hepatitis C virus genotype 3 in liver fibrosis 
progression - a systematic review and meta-analysis » 
et 
« Impact of a nurse vaccination 
program on hepatitis B immunity in a Swiss HIV clinic » 
THESE 
préparée sous la direction du Docteur PD Pierre-Yves Bochud 
(avec la co-direction du Professeur Thierry Clandra) 
et présentée à la Faculté de biologie et de médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
par 
Arnold PROBST 
Médecin diplômé de la Confédération Suisse 
Originaire de Berne 
Lausanne 
2012 [-)it1l1uthèque Universitaire 
de Médecine/ BiUM 
CHUV-BH08 - Bugnon 46 
CH-101 î Laus~:mne 
UNIL 1 Université de Lausanne 
ulté biologie Ecole Doctorale 
Doctorat en médecine et de médecine 
Imprimatur 
Vu le rapport présenté par le jury d'examen, composé de 
Directeur de thèse Monsieur le Docteur Pierre-Yves Bochud 
Co-Directeur de thèse Monsieur le Professeur Thierry Calandra 
Expert Monsieur le Professeur François Spertini 
Directrice de l'Ecole Madame le Professeur Stephanie Clarke 
doctorale 
la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de 
Monsieur Arnold Probst 
intitulée 
Role of Hepatitis C virus genotype 3 in liver fibrosis 
progression - a systematic review and meta-analysis 
& 
Impact of a nurse vaccination program on hepatitis B 
immunity in a Swiss HIV clinic 
Lausanne, le 18 octobre 2012 
pour Le Doyen 
de la Faculté de Biologie et de Médecine 
.~fl-9 
Madame le Professeur Stephanie Clarke 
Directrice de l'Ecole doctorale 
Cette thèse est composée de deux articles qui font suite à une recherche relative aux virus de l'hépatite B et 
C, dont voici les résumés : 
Rôle du génotype 3 du virus de l'hépatite C dans la progression de la fibrose hépatique, une revue 
systématique avec méta-analyse. 
On estime à 170 millions le nombre de personnes atteintes d'hépatite C chronique dans le monde. La 
principale conséquence de cette maladie est la fibrose du foie, qui évolue plus ou moins rapidement, pour 
aboutir au développement d'une cirrhose et/ou d'un hépatocarcinome. Certains des facteurs accélérateurs de 
la fibrose, comme l'âge avancé au moment de l'infection, le sexe masculin, la consommation d'alcool, sont 
bien connus. On a longtemps considéré que les six différents génotypes viraux n'influençaient pas la 
progression de la fibrose. Des études récentes ont cependant suggéré que certains génotypes, en particulier 
le génotype 3, pouvaient entraîner une fibrose plus rapide. 
Le but de ce travail de thèse était de déterminer à l'aide d'une méta-analyse le rôle du génotype viral dans la 
progression de la fibrose dans l'infection chronique au virus de l'hépatite C. Les études ont été sélectionnées 
dans la littérature médicale à partir d'une série de mots-clés. Le degré de fibrose a été estimé par biopsie, en 
utilisant le score Metavir. Deux types d'études ont décrits de manière différente la durée d'infection. Les 
premières ont calculé la progression de la fibrose depuis le moment estimée de l'infection ( « études avec une 
biopsie » ), les secondes ont exprimés cette durée comme étant l'intervalle entre deux biopsies ( « études avec 
deux biopsies » ). 
L'analyse a permis d'identifier 8 études avec une biopsie pour un collectif total de 3182 patients ainsi que 8 
études avec deux biopsies pour un collectif de 896 patients. Dans une méta-analyse de type « random 
effect », le rapport de cote pour l'association du génotype 3 avec une fibrose accélérée est de 1.52 (95% IC 
1.12-2.07, p=0.007) pour les études à une biopsie. Pour les études à deux biopsies, le rapport de cote pour 
cette association est de 1.37 (95% IC 0.87-2.17, P=0.17). 
Cette étude montre que les patients avec une hépatite C chronique due au génotype 3 ont une progression 
de fibrose plus rapide que ceux qui sont infectés par les autres génotypes. Alors que la méta-analyse des 
études avec une biopsie est clairement significative, celle des études avec deux biopsies est au-dessous du 
seuil de significativité. Les études à deux biopsies peuvent être limitées par plusieurs facteurs, comprenant un 
« biais d'indication » (seuls les patients évoluant rapidement vers la cirrhose ont plus de risque d'avoir une 
deuxième biopsie), une durée d'observation très courte (5 années comparée à 13 années pour les études à 2 
biopsies), et un nombre de patient limité (896 pour le études à 2 biopsies comparé à 3182 pour les études à 1 
biopsie). 
Impact d'un programme de vaccination sur l'immunité contre l'hépatite B dans une clinique suisse du 
VIH 
Le virus de l'hépatite B cause une infection aigue dont la symptomatologie varie d'une présentation 
subclinique à une progression fulminante. Dans une minorité de cas, l'infection aigüe est suivie d'une infection 
chronique pouvant évoluer vers une cirrhose hépatique et/ou un hépatocarcinome. La prévalence de 
l'hépatite B aigüe et chronique chez les personnes vivant avec le virus d'immunodéficience humaine (VIH) est 
supérieure à celle de la population générale. Par ailleurs la co-infection avec le virus du VIH entraine une 
progression plus rapide de l'hépatite B. Dès lors, l'immunité pour le virus de l'hépatite B représente un facteur 
primordial de prévention dans la population infectée par le virus de l'HIV. Bien que l'administration d'un vaccin 
contre l'hépatite B soit particulièrement recommandée chez tous les individus infectés par le VIH, la 
couverture vaccinale dans cette population est souvent insuffisante. 
Le but de cette étude était de déterminer l'état d'immunisation contre le virus de l'hépatite B dans la 
population infectée par le VIH de la cohorte Suisse HIV et d'analyser l'efficacité d'un programme de 
vaccination administré par le personnel soignant. L'immunité avant et après intervention dans notre centre a 
été comparée aux autres centres de la cohorte HIV en Suisse. L'immunité pour le centre d'intervention a 
passé de 32% avant intervention à 76% après intervention alors que pour les autres centres, l'immunité n'a 
progressé que de 33% à 39% dans le même laps de temps (n=2712, P=0.001 ). Cette étude montre qu'un 
contrôle systématique de l'immunité par du personnel soignant augmente de manière significative l'immunité 
pour le vaccin de l'hépatite B dans la population HIV. 
Jo11mal of Viral Hepatitis, 2011, 18, 745-759 doi: 1O.1111/j.l3 fi5-289 3 .2011.01481.x 
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SUMMARY. The progression of liver fibrosis in chronic hep-
atitis C has long been considered to be independent from 
viral genotypes. However, recent studies suggest an associ-
ation between Hepatitis C virus (HCV) genotype 3 and 
accelerated liver disease progression. We completed a sys-
tematic review and meta-analysis of studies evaluating the 
association between HC\I genotypes and fibrosis progression. 
PubMed, Embase and ISI Web of Knowledge databases were 
searched for cohort. cross-sectional and case-contrai studies 
on treatment-naïve HC\1-infected adults in which liver 
fibrosis progression rate (FPR) was assessed by the ratio of 
fibrosis stage in one single biopsy to the duration of infection 
(single-biopsy studies) or from the change in fibrosis stage 
between two biopsies (paired biopsies studies). A random 
effect mode! was used to derive FPR among different HCV 
genotypes. Eight single-biopsy studies ( 3182 patients, me an/ 
median duration of infection ranging from 9 to 21 years) 
INTRODUCTION 
The hepatitis C virus (HCV) chronical!y infects ~ 170 mil-
lions of persans worldwide, which represents ~3% of the 
world's population [l]. The important morbidity and mor-
tality associated with chronic hepatitis C result mainly from 
the development of liver fibrosis and its evolution towards 
cirrhosis and hepatocarcinoma [2]. The identification of 
Abbreviations: DAA, direct antiviral agents: ES, effect size; FPR, 
librosis progression rate; HAI, histology aclivily index; HBV, hepa-
tilis B virus: HCV, hepatilis C virus; HIV, hnman immunodeliciency 
virus; OR, odds ratio; RNA, ribonucleic acid. 
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and eight paired biopsies studies (mean interval between 
biopsies 2-12 years) met the selection criteria, The odds 
ratio for the association of genotype 3 with accelerated 
fibrosis progression was 1.52 (95% CI 1.12-2.07, P = 
0.007) in single-biopsy studies and 1.3 7 (9 S'Y,, CI 0.8 7-2.17, 
P = 0.17) in paired biopsy studies. In conclusion, viral 
genotype 3 was associated with l'aster fibrosis progression in 
single-biopsy studies. This observation may have important 
consequences on the clinical management of genotype 
3-infected patients. The association was not significant in 
paired biopsies studies, although the latter may be limited by 
important indication bias, short observation time and small 
sample size. 
Keywords: fibrosis progression, genotype 3, hep a titis C, meta-
analysis. 
factors affecting fibrosis progression is critical for the optimal 
management of infected patients [3]. Factors associated with 
rapid progression include demographic characteristics (such 
as older age at infection and male sex), host genetic factors, 
viral co-infections (with the hepatitis B [HBV] or the human 
immunodeficiency virus [HIV]), metabolic features (such as 
steatosis, insulin resistance or iron overload) and exposure to 
toxic agents (alcohol, tobacco or cannabis) [4]. Risk factors 
identification for fibrosis progression was first based on 
fibrosis stage. However, this approach leads to significant 
bias, because disease duration varies widely across the 
population. This issue has been addressed, at least in part, by 
the estimation of fibrosis progression rate (FPR) based on the 
ratio of fibrosis stage to disease duration, which might better 
reflect the true fibrosis progression. Recent studies, using the 
latter method, suggested that some viral genotypes, such as 
genotype 3, are associated with more rapid fibrosis 
progression than other genotypes [5-7]. In this study, we 
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systematically reviewed the published literature about the 
impact of HCV genotypes on the natural history of chronic 
hepatitis C and conducted a meta-analysis of the studies 
reporting a FPR per genotype. Our aim was to examine the 
impact of viral genotype 3 on fibrosis progression compared 
with other genotypes. 
MATERIAL AND METHODS 
Searclz strategy 
This meta-analysis was perfonned according to the PRISMA 
statement for reporting systematic reviews and meta-anal-
yses [8]. Three electronic databases (PubMed, Embase and 
ISI Web of Knoweldge) were searched for published studies 
evaluating the fibrosis progression per genotype in chronic 
HCV before October 2009 (Table Sl). Additionally, the 
investigators hand-searched the bibliographies of obtained 
articles and reviews; they did not contact any study authors 
for further information. 
Eligible studies 
Cohort, cross-sectional and case-contrai published trials 
studying the fibrosis progression in HCV-infected patients 
were eligible. There was no restriction on language or pub-
lication date. Participants were chronically infected with 
HCV genotype 3, and contrais were chronically infected with 
other genotypes. 
Study selection 
Two investigators independently selected studies meeting the 
following criteria (Table Sl ): (i) chronic HCV infection; (ii) 
fibrosis scoring; (üi) no HCV treatment before biopsies; (iv) 
an estimated date ofHCV infection; and (v) an estimated FPR 
per genotype. Studies on participants of < 18 years of age, 
studies on orthotopic liver transplant recipients, studies 
without full text available and reviews were excluded. When 
more than one article was available from the same cohort, 
we included the article containing most complete informa-
tion. Disagreements between the two investigators were 
solved by discussion. 
Study quality assessment and data extraction 
Quality criteria were reported for each study, including study 
design, case definition, liver biopsy quality, nonviral factors 
associated with fibrosis progression and method used to 
estimate the date of infection (Table Sl). The two investi-
gators independently extracted data for each study. The 
extracted data were then cross-checked by two other 
investigators for accuracy. FPR values were assessed 
together for ail genotype non-3 patients. Patients with 
unknown genotype were not included. 
Statistical analysis 
Eligible studies were separated in two groups: those calcu-
lating FPR as the ratio of the fibrosis score to the interval 
between an estimated date of infection and one pretreatment 
liver biopsy (defined as 'single-biopsy studies') and those 
calculating fibrosis progression between two pretreatment 
liver biopsies ('paired-biopsies studies'), For single-biopsy 
studies, an effect size (ES) was calculated for each individual 
study (detailed in Appendix) [9]. ES of both continuous and 
dichotomous outcomes was pooled in the same meta-anal-
ysis using a random effect mode! [10]. ES was then trans-
formed back to odds ratio (OR). For paired biopsies studies, 
the OR for comparison of genotype 3 vs others was calcu-
lated for each individual study. We performed a meta-anal-
ysis by pooling the OR using a random effect mode!. Ail 
statistical analyses were perfonned with Stata software 
(StataCorp, College Station, TX, USA), version Hl.O. 
RESULTS 
From the 313 3 citations yielded by the electronic database 
search, 2936 were excluded for nonrelevance after title or 
abstract screenings (Fig. 1). Among 19 7 remaining full-text 
papers, 181 were excluded for nonrelevance, inappropriate 
review design, use of post-treatment biopsy, lack of estimated 
HCV infection duration, or Jack of data on genotyping (no 
data on genotype 3) or FPR. The remaining 16 studies ( eight 
single-biopsy and eight paired biopsy studies) were selected 
for the meta-analysis. For single-biopsy studies in which 
both continuous and dichotomous outcomes were available 
[6,7], the continuons outcome was used. 
The characteristics of the studies are shown in Table 1. In 
most studies, the primary endpoint was to assess together 
the raie of several risk factors on fibrosis progression in 
chronically HCV-infected patients (N = 7 [6,7,11-15]). No 
study focused specifically on the raie of viral genotypes, but 
some addressed specific factors su ch as steatosis ( N = 5 [ 16-
20]), cannabis use (N = 1 [5]), host genetic variants (N = 1 
[21]), immunosuppression level in HIV-infected patients 
(N = 1 [22]) or transforming growth factor (3 (N = 1 [23]). 
Overall, 3860 patients were included in the meta-analy-
ses, 3182 (range 71-1157) from single-biopsy studies and 
678 (range 20-136) from paired biopsies studies (Table S2). 
Most patients included in the studies were men (62%), the 
most frequent ethnicity was Caucasian (9 5'Yt,, data available 
in five studies) and the mean age was 42 years. The most 
frequent routes of infection were intravenous drug use 
(41%) and blood transfusion (31%). Eight studies included 
only HCV mono-infected patients (N = 8), two included 
both HCV mono-infected and HCV /HIV co-infected patients 
(percentage of co-infection 7% and 22%), two included only 
co-infected patients, while four other studies did not give 
any information on co-infection. The mean duration of 
HCV infection in single-biopsy studies was 13 years (range 
© 2011 Blackwell Publishing Ltd 
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publication 
Kanzler 
et al .. 
2001 
[23] 
Westin 
et al .. 
2002 
[18] 
Martinez-
Sierra 
et al.. 
2003 
[12] 
Study 
Country design 
Germany R 
Sweden R 
Spain P case-
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infected 
patients 
N 
li ver 
biopsy 
per 
Outcome subject 
TGF-/3 and 2 
fibrosis 
progression 
FPR 2 
FPR 
Fibrosis 
scoring 
system 
Ishak 
HAI [25J + 
Chevallier 
[40] 
Ishak 
HAI 
Desmet 
[27] 
Biopsy 
quality 
(length of 
biopsy) 
and 
assessment 
(number of Population 
pathologist) size. total 
No mention: 39 
two 
blinded 
pathologists 
No mention: 78 
two blinded 
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gists and 
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pathologist 
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experienced 
pathologist 
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estimated 
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a. 41 
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infection genotyping 
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publication 
Zarski 
et al., 
2003 
[14] 
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et al .. 
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[19] 
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et al., 
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[5] 
Richardson 
et al., 
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[21] 
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Country design 
France. R 
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France R 
France p 
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centre of fibrosis 
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Consecutive FPR 1 
patients in 
one liver 
centre 
One tertiary Host 1 
centre; genetic 
a. Consecu- polymor-
tive patients phisms 
with pre- and FPR 
treatment 
biopsy 
b. Validation 
group of 24 
li ver 
transplant 
recipients 
Biopsy 
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(length of N genotype 
biopsy) Method 3 with 
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system pathologist) size. total infection infection genotyping 3 (%) progression 
META VIR 220mm; 180 147 136 21 (15) 21 
one 
blinded 
pathologist 
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blinded 
pathologist 
META VIR No 270 270 First reported 2 6 7 66 (25) 66 
mention; event at 
one risk 
pathologist ::i:; 
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et al., 
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centre: and FPR b. 2 
a. Treat 
ment-naïve 
patients 
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HIV co- FPR 2 
infected 
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scoring 
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Biopsy 
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(length of 
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and N with used 
assessment estimated to assess 
(number of Population duration of date of 
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one 
blinded 
pathologist 
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study 
pathologist. 
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experienced 
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pathologist 
a. 494 494 
b. 136 
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Nwith Nwith 
HCV genotype 
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Citations identified through MEDLINE 
(2192), Embase (2048) and ISI Web 
of Knowledge (740) search 
(published before October 2009) 
(N = 4980) 
Citations after duplicates removed 
(N=3133) 
Tilles or abstracts (when available) 2936 articles excluded due to non-
-screened (N = 3133) relevance 
Full-tex! articles assessed for 181 Articles excluded due to: 
. 
eligibility (N = 197) 
non relevance (N = 36) -
- review (N = 32) 
- biopsy performed after antiviral 
treatment (N = 2) 
- no data on HCV infection 
duration (N = 2) 
- no HCV genotyping performed 
or published (N = 10) 
- only one genotype analyzed 
- duplicate cohort (N = 3) 
- no data on fibrosis progression 
(N= 35) 
- no data on fibrosis progression 
Studies included in Meta-analysis for genotype 3 (N = 59) 
(N= 16) - no full-text available (N = 2) 
Fig. 1 Flow diagram for study selection. 
10-17, six studies; median 9 and 21 years in two other 
studies). The mean interval time between paired biopsies was 
5.3 years (range 2.3-12, 5 studies; median 4.1. 4.2 and 
6 years in three other studies). 
Study quality 
The studies showed a relative homogeneity in terms of 
design and settings: 11 were retrospective cohort studies 
(Table 1), four were prospective cohort studies and one was 
a retrospective case-control study. Ali studies performed in 
tertiary hospitals or liver centres, and ail published between 
1997 and 2009 (Table 1). Seven studies gave a fibrosis score 
according to the METAVIR system [24], while four used 
Ishak's modified histology activity index (HAI) [2 5], three 
used the Knodell's HAI [26], one used Desmet's system [27] 
and one study gave Scheuer's grades [28] (scores summa-
rized in Table S3 ). In most single-biopsy studies (N = 6), the 
date of infection was considered to be the first reported event 
at risk (blood transfusion, IV drug or nosocomial infection). 
In most studies, the association of viral genotype 3 with FPR 
was solely assessed in univariate models, with multivariate 
analyses performed in only three single-biopsy studies 
(Fig. SI). 
Meta-analyses 
The meta-analysis of single-biopsy studies showed a faster 
FPR in patients infected by genotype 3 compared with the 
others (overall pooled ES= 0.23, [95% CI 0.06-0.40], 
P = 0.007, OR= 1.52 [95% CI 1.12-2.07], Fig. 2). The J2 
test result was 62.2% (P = 0.010). Similar results were 
obtained when studies including HIV-infected patients were 
removed, but the number of patients was smaller (N = 455) 
and the association was at the limit of significance 
(OR = 1.67, [95% CI 0.99-2.85], P = 0.056). The cumu-
lative meta-analysis showed that the effect of genotype 3 on 
fibrosis progression became significant only in 2009 (Fig. 3 ). 
The meta-analysis of paired biopsies studies showed a trend 
towards faster progression for genotype 3 patients compared 
© 2011 Blackwell Publishing Ltd 
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Year ES (95% Cl) OR (95% Cl) N genotype N other Weight 
3 genotypes (%) 
1 
1 
Poynard 1997 1 0.01 (-0.19-0.22) 1.03 (0.71-1.49) 39 207 16.81 
---+-1 
Adinolfi 2001 
1 
0.44 (-0.09-0.97) 2.21 (0.85-5.75) 25 15 6.97 
Martinez-Sierra 2003 0.01 (-0.30-0.31) 1.01 (0.58-1. 76) 56 132 12.98 
Hezode 2005 
1 
0.77 (0.43-1.11) 4.01 (2.16-7.45) 66 201 11.66 
Richardson 2005 -0.01 (-0.34-0.32) 1.36 (0.75-2.47) 88 117 11.91 
1 
1 
Bochud 2009 -;--- 0.23 (0.09-0.37) 1.51 (1.17-1.95) 327 862 19.47 
1 
1 
Hissar 2009 0.32 (0.01-0.63) 1.78 (1.02-3.11) 105 35 12.87 
Reiberger 2009 1 0.32 (-0.19-0.83) 1.78 (0.71-4.49) 24 50 7.33 
1 
Ove ra li <I> 0.23 (0.06-0.40) 1.52 (1.12-2.07) 730 1619 100.00 
(1 2 = 62.2%, P = 0.01) 1 1 
1 
0 1.11 
Fig. 2 Forest plot of fibrosis progression rates estimated from one biopsy, genotype 3 vs other genotypes. ES, effect size; OR, 
odds ratio; 95% CI, 95% confidence interval. 
Study Year ES (95% Cl) OR(95% Cl) N genotype 3 N other 
genotypes 
Poynard 1997 0.01 (-0.19-0.22) 1.02 (0.71-1.49) 39 207 
Adinolfi 2001 0.15 (-0.24-0.54) 1.31 (0.65-2.66) 64 222 
Martinez-Sierra 2003 - r+--- 0.06 (-0.12-0.24) 1.11 (0.80-1.54) 120 354 
Hezode 2005 0.28 (-0.09-0.65) 1.66 (0.85-3.24) 186 555 
Richardson 2005 0.22 (-0.08-0.52) 1.49 (0.87-2.56) 274 672 
Bochud 2009 0.21 (0.01-0.42) 1.46 (1.01-2.14) 601 1534 
Hissar 2009 0.23 (0.05-0.41) 1.52 (1.09-2.10) 706 1569 
Reiberger 2009 0.23 (0.06-0.40) 1.52 (1.12-2.07) 730 1619 
1 
0 0.65 
Fig. 3 Meta-cumulative analysis of studies estimating fibrosis progression rate based on an estimated date of infection, 
genotypes 3 vs non-3. ES, effect size; OR, odds ratio; 95'}(, CI, 95% confidence interval. 
with the others (OR= 1.37, 95% CI 0.87-2.17, P = 0.17, 
Fig. 4). The I2 test was 0.0% (P = 0.455). The dichotomi-
zation process differed widely across studies, with a pro-
gression definition ranging from a worsening of fibrosis unit 
between two biopsies to a fixed higher fibrosis score value at 
the second biopsy (Table 2). 
DISCUSSION 
Viral factors have usually been considered to have limited 
influence on liver FPR in chronically infected HCV patients 
[29]. However, recent studies highlighted a possible associ-
ation between viral genotypes and rapid fibrosis progression. 
By pooling results from several, often small-sized studies, this 
meta-analysis provides a comprehensive summary of the 
© 2011 Blackwell Publishing Ltd 
published literature on the tapie as well as new insights into 
the natural history of chronic HCV infection. The pooled 
analyses of eight single-biopsy studies clearly confirmed a 
significantly faster progression for genotype 3 patients 
compared with the other genotypes. Among them, !ive 
showed a significantly faster fibrosis progression or a clear 
trend towards faster progression for genotype 3-infected 
patients cornpared with others [5-7,16,22]. The failure of 
some studies to detect a significant effect for viral genotype 3 
probably results from their insufficient sample size (i.e. 342 
cases and 684 contrais are necessary for 80% power to 
detect an OR of 1.5 for viral genotype 3 on fibrosis pro-
gression, considering a 30'}(, prevalence of this genotype). 
Despite a much smaller observation time, the pooled analysis 
of eight paired biopsies studies showed a trend towards faster 
754 A. Probst et al. 
Study 
Shev 
Kanzler 
Westin 
Zarski 
Fartoux 
Perumalswami 
Bonnard 
Cross 
Overall 
(1 2 = 0.0%, 
p = 0.455) 
Year 
1997 
2001 
2002 
2003 
2005 
2006 
2007 
2009 
0.05 
OR(95% Cl) N Genotype 3 N other Weight 
(Fibrosis genotypes 
progression (Fibrosis 
/ail) progression 
/ail) 
0.80 (0.10-6.25) 4/6 10/14 4.99 
0.88 (0.07-10.75) 213 25/36 3.37 
0.88 (0.32-2.40) 12/22 30/52 20.95 
1.63 (0.64-4.18) 10/21 39/109 23.79 
4.33 (1.45-12.89) 7122 11/113 17.10 
0.50 (0.05-4.98) 1/4 49/123 4.02 
1.36 (0.20-9.27) 217 5/22 5.73 
0.96 (0.34-2.71) 6/30 17/82 19.44 
1.37 (0.87-2.17) 44/115 186/551 100.00 
Fig. 4 Forest plot of odds ratio of fibrosis progression betwecn two liver biopsies, genotype 3 vs non-3, OR, odds ratio; 9 5% CI, 
9 5% confidence interval. 
progression for genotype 3-infected compared with genotype 
non-3-infected patients. 
A previous study assessing stage-specific FPR using a 
Markov mode! suggested that viral genotype 1 ( compared 
with other genotypes) may influence fibrosis progression, 
but the estimation was performed using a meta-regression 
[30], It is known that such ecological associations may 
lead to incorrect estimates of the relation for individual 
patients. 
The association of viral genotype 3 with FPR may have 
important practical implications. It has been reported that 
the uptake of antiviral therapy for hepatitis C has been 
declining during recent years [31], Apart from poor rate of 
diagnosis and lack of referral. two major factors may 
account for this trend: the widespread perception on the 
supposedly slow average progression rate of hepatitis C, 
coupled with the huge expectations surrounding nove!, more 
effective direct antiviral agents (DAA), to be first marketed in 
2011-2012. Genotype 3-infected patients should be aware 
of a potentially faster progression rate and may benefit from 
individualized counselling, with particular attention given to 
the controllable factors, such as alcohol consumption and 
overweight [32]. While therapy with peginterferon alpha 
and ribavirin usually achieves 70-80% of sustained viral 
response among patients infected with HCV genotype 3, 
certain subgroups of patients still have high relapse rates, 
such as those with elevated baseline viral load (>800 000 
copies/mL, [33,34]) and advanced fibrosis [32]. Patients 
with chronic hepatitis C may be deferred from current 
treatment regimens just because more patent DAA will be 
licensed in the near future [ 3 5]. However, this 'warehousing' 
attitude may not be justified in infections with genotype 3, 
given that the serine protease inhibitors, such as telaprevir, 
have very limited activity against genotype 3 [36]. DAAs 
with significant activity against genotype 3, such as the 
nucleoside RNA polymerase inhibitor R7128 [37] or the 
cyclophilin-binding molecule Debio 025 r38], are far from 
completing clinical development. These considerations argue 
against the indiscriminate deferral from antiviral therapy in 
patients infected with genotype 3. 
Multiple reasons may explain why paired biopsies studies 
did not show a significant effect of genotype 3. First, con-
founding by indication is likely to be a major problem in 
paired biopsies studies. as only selected patients undergo a 
second biopsy (e.g. those with multiple comorbidities and 
potentially rapidly evolving liver disease). Second, paired 
biopsies studies have a smaller sample size than single-biopsy 
studies. Out of eight studies, none included more than 30 
genotype 3 patients, and four included < 7 genotype 3 
patients, resulting in low power to detect a given ES. Third, 
paired biopsies studies have a much smaller observation time 
than single-biopsy studies ( ~ 5 years between 2 biopsies 
compared with ~ 13 years from the infection date to the first 
biopsy, Fig. S3 ). This short duration may not be sufficient to 
detect genotype-specific differences in terms of FPRs. Fourth, 
paired biopsies studies have used arbitrary eut-offs for 
dichotomizing the outcome into progression vs nonprogres-
sion, for instance a worsening of the score by one or several 
units [13-15,17,18,20,23] or reaching a specific fibrosis 
stage at the second biopsy [19]. This method results in more 
information loss if one considers that the process of fibrosis is 
continuons. Finally, given that FPRs are not constant over 
time, paired biopsies studies may have included patients 
when the progression rate is the slowest (e.g. transition from 
Metavir scores Fl-F2 [30] or F2-F3 [7]), making it even 
more difficult to detect genotype-specific differences (Fig. S2 ). 
© 2011 Blackwell Publishing Ltd 
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"""' Table 2 Characteristics of participants in studies included in the meta-analysis ~ 
Reference 
N participants. 
(N assessable) 
Mean age at 
biopsy 
in years ( ±SD 
or 95% CI) 
Mean age at 
infection 
(±SD or 
95% CI) 
Studies with FPR based on presumed date of infection and 1 liver biopsy 
Poynard 1157 (246) 46 (45-47) 
et al. [11] 
Adinolfi 
et al. [16] 
Martinez-Sierra 
et al. [12] 
Hézode 
et al. [5] 
Richardson 
et al. [21] 
Bochud 
et al. [7] 
Hissar et al. [ 6] 
Reiberger 
et al. [22] 
71 (40) 49t (range 
20-66) 
188 (188) 38 (34-39) 
267 (267) 43 (±10) 
205 (205) 40 (±8) 
1189 (1189) 42·1· (IQR 13) 
140 (140) 42 (±15) 
74 (74) 37 (±10) 
111· (19-23) 
24 (±10) 
22 (±8) 
19t (IQR 9) 
29t 
24 (±8) 
Mean duration of 
HCV infection 
in years ( ±SD or 
95%CI) 
12.4 
(11.9-12.9) 
Genotype la:l5t 
(range 6-24) 
Genotype 3a: 9·1· 
(range 3-18) 
17.2 (16-19) 
10 (±7.8) 
17.6 (±8.5) 
11 ·1· (IQR 13) 
12.1 (±8.9) 
13 (±5) 
Mean FPR 
per year for Mean FPR 
genotypes 3 for genotypes 
(±SD or non-3 (±SD or 
95% CI), 95% CI). 
N of patients N of patients 
O.li 0.12·1• 
(0.13-0.22). N = 207 
N = 39 
0.11 (±0.02). 0.07 (±0.01. 
N = 25 genotype la 
only), N = 15 
0.15 (0.10-0.20). 0.14 
N = 56 (0.11-0.016). 
N = 132 
Proportion of Proportion of 
rapid progressort rapid progressort 
49/66 (74%) 84/201(41 %) 
::r: 
Proportion of Proportion of ri 
rapid progressor§ rapid progressor§ ~ 
"" :::::26/88 (30%) 351117 (30%) ~ 
CJ.10. N = 327 0.07 (genotype 1 E§ 
"' only). N = 862 w 
Cl.28 (±0.27). 0.24 (±0.17). a s_ 
N = 105 N = 35 ';::t, 
0.22 (±0.09). 0.19 (±0.08. <::;" 3 
"' N = 24 genotype 1 t;;· 
only). N = 50 ~ 3 
"" ;;; 
"' ~-§ 
'-! 
V1 
V1 
Table 2 (Continued) 
Median age at Median time Genotype 3: Genotype non-3: 
N Mean age at first biopsy between two proportion proportion with 
Dichotomization participants, infection in years biopsies in years with fibrosis fibrosis 
Reference process (N assessable [7]) (±SE or range) (range) (range) progression (%) progression (%) 
Studies with FPR estimated between 2 liver biopsies 
Shev Knodell total score 20 (19) 30 (16-56) 12 (9-16) 4/6 (67) 10/14 (71) 
et al. [13] worsening by 
:2:2 units between 
biopsies 
Kanzler Knodell/ Chevallier 39 (39) 2.3 (1-5.1) 2/3 (66) 25/36 (69) 
et al. [23] fibrosis score 
worsening by :2:1 unit 
Westin Ishak fibrosis score 74 (74) a. Progressor: 3 7'1 a. 6.5·r· (IQR 12/22 (55) 30/52 (57) 
et al. [18] worsening by :2:1 unit b. Non-progressor: 34·1· 3.9-10.6) 
b. s.5·r (IQR 
2.5-7.7) 
Zarski META VIR fibrosis 130 (130) 26 (±12) 3.6 (±2.6) 10/21 (48) 39/109 (36) 
et al. [14] score worsening 
by :2:1 unit 
Fartoux META VIR fibrosis 135 (135) 5.0 7122 (32) 11/113 (10) 
et al. [19] score of 3 or 4 (1.5-13.16) 
at second biopsy 
Perumalswami Ishak fibrosis score 136 (127) 29 (8-67) a. Progressor: 3.6 (0.5-17) 114 (25) 49/123 (40) 
et al. [20] worsening by :2:1 unit 44 (21-67) 
b. Non-progressor: 
41 (19-67) 
Bonnard META VIR fibrosis score 32 (29) a. Rapid progressor: 4.1·1 (2-6.7) 217 (29) 5/22 (23) 
etal. [15] worsening by :2:2 units 451' (34-53) 
b. Slow progressor: 
43·1• (35-64) 
Cross et al. [17] Ishak fibrosis score 112 (106) 44·1· (IQR 39-51) 4.2°1. (IQR 2.8-6) 6/30 (20) 17/76 (22) 
worsening by :2:1 unit 
N, number: SD, standard deviation: SE. standard error: FPR. fibrosis progression rate: CI. confidence interval: IQR. Interquartile Range. 
·i·Denotes median (95% CI. IQR or range) instead ofmean. tRapid progressor = Fibrosis progression rate >0.074 U/year META VIR. §Rapid progressor = Scheuer stage 3 or 4 
on biopsy or fibrosis stage 2 on biopsy :O;l 0 years after HCV acquisition. 
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HCF genotype 3 and fibrosis progression 7 5 7 
As in many systematic reviews, the limitation of this study 
results from the limitation of the original studies themselves. 
Those include the inability to precisely determine the date of 
infection, the variability in the assessment of fibrosis staging, 
the nonlinearity of fibrosis progression over time, the failure 
to account for multiple risk factors. However, several studies 
addressed these issues. In three studies, the role of viral 
genotype 3 in fibrosis progression was confirmed in multi-
variate analyses, accounting for different covariates such as 
age, alcohol consumption and steatosis [5-7]. In one of 
them, the authors suggested that cannabis use, which may 
be more prevalent among genotype 3-infected patient, may 
have been a confounding factor for the role of genotype 3. 
However, this study clearly identified cannabis use, genotype 
3, age at infection, alcohol intake and steatosis ail as inde-
pendent risk factors for rapid fibrosis progression (>O. 7 4 U/ 
year) in a stepwise logistic regression mode! of 267 patients 
[5]. In another study, the association of genotype 3 with 
faster progression remained significant among patients 
infected by blood transfusion (for whom the date of infection 
is certain), among different age groups, or among different 
periods of infection, and when using different methods to 
assess the progression rate [7]. 
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properties of the variance. We derived 
ES and standard deviations from FPR 
using the unbiased estimate of Hedges' 
effect size (9). For each study giving 
FPR as a dichotomous outcome, the 
odds ratio (OR) for comparison of 
genotype 3 vs others was calculated. 
We converted OR to ES by using the 
method described by Chinn (lCl). The 
author shows that when assuming a 
logistic distribution with equal var-
iances between the two groups, the 
natural logarithm of the OR equal a 
constant multiplied by the ES. The 
standard logistic distribution has var-
iance n2 /3, so a difference in ln(OR) 
© 2011 Blackwell Publishing Ltd 
can be converted to an approximate ES 
by dividing the ln(OR) by n/'1/3 which 
is 1.81. For both meta-analyses, we 
calculate the statistical heterogeneity 
using a I2 calculation. This calculation 
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provides an estima te of the variation of 
variance among studies due to true 
heterogeneity rather than chance. 
Publication bias was graphically eval-
uated using a funnel plot of the ES (or 
Figure S3. Mean or median obser-
vation time in studies evaluating FPR 
either between an estimated date of 
infection or between two biopsies. 
Table Sl: Detailed material and 
methods. 
Table S2: Further characteristics of 
participants in studies included in 
meta-analysis. 
Table S3: Liver fibrosis staging. 
OR) for asymmetry resulting from the 
nonpublication of small negative stu-
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Please note: Wiley-Blackwell are not 
responsible for the content or func-
tionality of any supporting materials 
supplied by the authors. Any queries 
(other than missing material) should 
be directed to the corresponding 
author for the article. 
BRIEF REPORT: CLINICAL SCIENCE 
Impact of a Nurse Vaccination Program on Hepatitis B 
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Abstract: We evaluatccl the impact of a nurse program for hcpatitis 
B virus vaccination in a ccnter from the Swiss HIV Cohorl Study. 
Immunity (anti-HBs > 10 IU/mL) incrcasecl from 32°1(, to 76''1(, in the 
intervention cent cr ( n = 238) whcre vaccine management was 
enclorsccl by nurses. but only from 33% to 39'X1 in control centers 
( n = 2712. P < 0.00 1) wherc management remainecl in charge of 
physicians. Immunity against HBV in the HIV population is insuf-
ficient in Switzcrland. Spccific nurse vaccination progrnm may c!Ii-
ciently improvc health carc. 
Key Words: I-lcpalitis B. I-11\1. nurse intervention. vaccination. 
vaccination covcrage 
(./ Acq11ir l1111111111c Dcfic Smdr 2011:58:472 474) 
INTRODUCTION 
Hepatitis B virus (HBV) can cause acute infection 
ranging from asymptomatic to fulminant hepatitis ( < 1 %) 
depending on various host and viral factors. Chronic infection 
leading to cirrhosis and hepatocellular carcinoma occurs 
in a minority of patients. The incidence of acute HBV in-
fection is higher in HIV-positive patients than in the general 
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population ( 12.2 versus 0.33 cases/ 1000 person-years). Sim-
ilarly, the prevalence of chronic HBV infection is higher 
in HIV-positive patients than in the general population 
(4'%-10'% versus <1%i). 1 
The rnost efficient way to prevent HBV infection is 
vaccination, which is recornrnended by the Centers for 
Disease Contrai and Prevention for every HIV-positive 
patient. 2 HBV vaccine is safe and efficient. However, its im-
munogenicity is lower in HIV-positive patients (l8'Y.1-6I'%) 
compared with immunocompetent subjects (90%-95%).-' 
Risk factors for nonresponse to vaccination include older 
age. alcohol abuse, high HIV RNA. low CD4 T-cell count. 
and absence of combination antirelroviral therapy .' The num-
ber of vaccinated HIV-positive patients is largely insufficient 
in most countries. with 14%-62% of patients receiving at 
least 3 doses of vaccine. 14 
Strategies to improve the rate of HBV vaccination 
among high-risk populations included mainly free vaccination 
programs delivered to sex workers, men having sex with men. 
intravenous drug users or homeless. 5 7 To our knowledge, 
no studies have evaluated the efficacy of HBV vaccination 
programs in clinical practice among HIV-positive patients, 
population with a better follow-up than the population 
included in the aforementionecl studies. 
ln 2006, an external audit in the Lausanne HIV center 
of the Swiss Hl\/ Cohort Study (SHCS) showed that the 
medical files failed to report 1-IBV vaccination coverage and 
immunity. We investigated the effectiveness of a nurse inter-
vention program for systematic chart review and HBV 
vaccine management in our center. 
METHODS 
Patients recorded in the SHCS on Janumy 1, 2007, were 
eligible for the study. The SHCS is an ongoing, continuous 
enrollment prospective observational cohort of HIV- l-
infected patients followed at 7 medical centers in Switzerland. 0 
Patients have been enrolled since 1988 and signed written 
consent for data collection and blood sampling. Ethical 
approval for this research was obtained from the institutional 
review boards. Ali SHCS pa1iicipants were included in the 
study, except pmiicipants with previous HBV infection (anti-
HBc or HBs antigen positive). Patients who were immune 
(anti-HBs ~ 10 IU/L), not immune (negative HBV serologic 
markers), or had an unknown immunity (no anti-HBs check) 
for HBV in January 2007 were followed up until June 2010. ln 
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addition, nonimmune patients ( anti-HBs < 10 IU/L) and 
patients with unknown immunity were eligible for nurse vac-
cination program in the intervention center. Six other centers 
of the SHCS did not undergo any vaccine intervention and 
were used as control. ln all these centers. HBV vaccination 
was prescribed by the physician in charge of the patient. The 
nurse intervention consisted of ( 1 ) docurnenting HBV seros-
tatus in all patients with previously missing information, (2) 
providing vaccination (3 doses with a minimal interval of l 
and 6 rnonths) to all nonimmune patients. ( 3) rneasuring vac-
cination effectiveness 1-12 months after the third dose. and 
( 4) providing a second course of vaccination ( according to the 
physician in charge) to nonresponders (anti-HBs < l 0 IU/L ). 
Clinical and demographic data were extracted from the SHCS 
database. Because vaccination histmy is not recorded in the 
SHCS database. it was obtained frorn medical records at the 
intervention center only. 
HBV vaccine is available as a single-antigen formulation 
and in fixed combination. Two single-antigen formulations 
are available in Switzerland: Engerix-B (GlaxoSmithKline 
Biologicals. Rixensart. Belgium) and HBV AXPRO (Merck 
Research La bora tories. West Point. PA). One combination 
vaccine is available for aclults: Twinrix (GlaxoSmithKline 
Biologicals. Rixensart. Belgium). Engerix and Twinrix for-
mulations contain 20 /J,,g and HBV AXPRO l 0--40 /J,,g/ml of 
HBsAg protein. 
Group comparison was clone using Ttest for continuous 
variable or x2 test for categorical variable. Statistical level 
for significance were assignecl for P value lower than 0.05. 
Logistic regression was used for univariate and multivariate 
calculation of miels ratios. Variables with a significant P value 
on univariate analysis were used as covariate in the multivar-
iate mode!. Statistical analyses were performecl using Stata 
software (StataCorp. College Station, TX .. version 11.1 ). 
RESULTS 
Arnong 6098 study patients, 3148 had a previous HBV 
infection (anti-HBc or HBs antigen positive). Among the 
2950 uninfected patients, only 956 (32%,) were immune 
against HBV, although 1782 ( 60'Yo) were not immune and 
212 (7%) had unlmown immunity (Fig. l ). Lack of HBV 
immunity was associated with older age (P < ().{JO l) and 
low CD4 T-cell counts (P = 0.006; see Table, Supplemental 
Digital Content 1, http://links.lww.com/QAl/A225). Infection 
by homosexual contact or IV drug use demonstrated reduced 
odds for Jack of immunity (P < 0.001 and P = 0.01, respec-
tively) compared with infection by heterosexual contact. Fur-
thermore. at baseline in January 2007. there was an important 
center effect (increased risk in centers 1, 3, 4, 5, 6 compared 
with center O. ail P < 0.001 ). ln the intervention center. among 
the 124 nonimmune patients before the vaccination program. 
58 (47%) were not vaccinated, 58 other (47%) were vaccine 
nonresponders after at least 3 vaccine closes, whereas the 
remaining 8 patients had an incomplete or undocumented 
vaccination. 
During the study period, the number of immune patients 
increasecl from 76 (32%1) to 180 (76%) in the intervention 
center, but only from 880 (33%) to 1057 (39%) in the control 
© 2011 Lippincotl Wi11iams & Wilkins 
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FIGURE 1. Evolution of the HBV immune status between 2007 
and 2010 in the intervention and contml centers. 
centers (ie. 13 7%, increase versus 20'% increase .. P < 0.001 ). 
The number of patients with undocumented serostatus 
decreasecl from 38 ( 16%) to 0 (O'Yri) in the intervention center. 
but only from 174 (6%) to 131 (5%) in the control centers 
(ie. l 00% versus 25%, decrease, P < 0.001, Fig. l ). 
Two patients (0.8°;(,) in the intervention center and 
19 (0.7%) in the control centers (P = 0.9) developed new 
HBV infections. ail of which resolved spontaneously. In the 
intervention center. l of the 2 infections occurred at the 
beginning of 2007 (ie. before vaccination was proposed) 
and the other occurred in a vaccine nonresponder. We do 
not have details on the vaccination history of the 9 patients 
followed up in the control centers. After the vaccination pro-
gram. 56 patients remained not immune in the intervention 
center. The reasons for persisting lack of immunity after 
the intervention were vaccine nonresponse (36 patients, 
64%) and vaccine refusa] ( 11 patients, 20%). Nine patients 
( 16%) were in the course of vaccination at the time of anal-
ysis. No factor was significantly associated with nonresponse 
to vaccination in the intervention center, but the number 
of vaccine responders (n = 60) and nonresponders (n = 54) 
were small. However patients with HCV coinfection and 
absence of combination antiretroviral therapy had a worse 
vaccine response (both P = 0.08) (see Table, Supplemental 
Digital Content 2, http://links.lww.com/QAI/A226). The 
majority of patients (68%) received Engerix vaccine 
www.jaids.com 1 4 73 
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formulation. The use of a specific type of vaccine did not 
influence vaccine response (see Table, Supplemental Digi-
tal Content 2, http://links.lww.com/QAI/ A226 ). 
DISCUSSION 
Overall. this study shows that HBV immunity is 
insufficient in HIV-positive patients in Switzerland and can 
be significantly improved by a nurse vaccination program. Tt 
demonstrated that nonresponse to vaccination bas only a rninor 
impact on HBV immunity among HIV-positive patients. 
Previously. intervention studies to improve the rate of 
HBV vaccination consisted mainly of free vaccine delivery 
to high-risk populations.' 7 \Ve identified only 3 studies in 
which the rate of vaccine coverage was reported before and 
after such an intervention. ln a study conducted in different 
medicalized or nonmedicalized locations. such as sexually 
transmitted disease clinics. sites of methadone outlet, gay 
bars. homeless shelter. brothels or zones of street prostitution. 
free immunization compared with simple flyers distribution 
improved full vaccine coverage from 4</'o to 13'%. 7 In another 
study performed in an urban sexually transmitted disease 
clinic .. proposing an HBV fact sheet with free immunization 
compared with no specific intervention resulted in an im-
provement of full-vaccine coverage from 5s<% to 62%.' A 
nurse-managed program consisting of informative sessions 
plus targeted hepatitis education and tracking arnong home-
less population versus standard targeted hepatitis education 
resulted in an improvement of full vaccine coverage from 
54<y,1 to 68%.<' Overall. previous interventions yielded only 
a modest improvement in HBV coverage compared with the 
marked irnprovement observed in our HIV clinic, where all 
patient charts were systematically reviewed. 
Factors associated with Jack of immunity in our study 
were older age and low CD4 T-cell count, which is 
concordant with previous studies (reviewed in 3 ). Infection 
through homosexual contact and intravenous drug use dem-
onstrated reduced odds for Jack of immunity, which is in 
opposition to other studies that observed lower seroconversion 
rates in homosexual compared to heterosexual patients.'J. 10 
The discordance with our results could be related the differ-
ence in vaccination rate rather than the availability to respond 
to vaccine. Indeed. these data suggest that homosexual and 
intravenous drug users have a higher vaccine coverage. We 
also found a strong center effect, which is concordant with 
another study. 11 The physicians are responsible for vaccina-
tion in every SHCS center, but the local habits and inclividual 
management may differ. 
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. Overall, this study highlights the weak immunity 
agamst HBV among HIV-positive individuals in Switzerland 
and the significant impact of nurse intervention to improve 
the rate of immunization in this population. 
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